Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02450812
Other study ID # 18043
Secondary ID XF 1503EUPAS2479
Status Completed
Phase
First received
Last updated
Start date May 28, 2015
Est. completion date September 17, 2020

Study information

Verified date October 2021
Source Bayer
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This observational prospective single arm cohort study is designed to assess overall survival, symptomatic skeletal event free survival and quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium- 223 under real life conditions. In addition, time to next tumor treatment (TTNT), mobility, quality of life and selfcare, independence in activities of daily living and safety will be assessed.


Recruitment information / eligibility

Status Completed
Enrollment 86
Est. completion date September 17, 2020
Est. primary completion date June 30, 2020
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male patients diagnosed with castration resistant adenocarcinoma of the prostate (CRPC) with symptomatic bone metastases without known visceral metastases - Decision to initiate treatment with Radium-223 was made as per investigator's routine treatment practice Exclusion Criteria: -Patients participating in an investigational program with interventions outside of routine clinical practice and also in all non-interventional studies focusing on Radium- 223-dichloride.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Radium-223-dichloride (Xofigo, BAY88-8223)
according to Summary of Product Characteristics

Locations

Country Name City State
Germany Many Locations Multiple Locations

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival (OS) Up to 60 months
Secondary Evaluation of symptomatic skeletal event free survival (SSE-FS) of mCRPC patients Up to 60 months
Secondary Estimation of the incidence of pathological fractures. Up to 60 months
Secondary Time to next tumor treatment(s) (TTNT) Up to 24 months
Secondary Incidence of treatment-emergent adverse events (TEAE) Up to 30 days after last administration of Radium-223
Secondary Quality of life as patient reported outcome estimated using Functional Assessment of Cancer Therapy - Prostate (FACT-P) questionnaire The FACT-P questionnaire version 4 is a 39-item questionnaire consisting of five domains; 'Physical well-being', 'Social/Family well-being', 'Emotional well-being', 'Functional well-being' and 'Additional concerns' (consisting of items relating specifically to prostate cancer and/or its treatment) and uses a 0-4 Likert-scale. Up to 60 months
Secondary Activities of daily living assessed according to the Katz-Index Up to 7 months
Secondary Body function assessed in dimensions of "mobility", "self-care" and "domestic life" using the Medical Oncology Status in Europe Survey (MOSES) questionnaire Up to 7 months
Secondary Estimation of the non-pathological fractures Up to 60 months
Secondary Estimation of the bone associated events Up to 60 months
See also
  Status Clinical Trial Phase
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Withdrawn NCT03325127 - Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
Withdrawn NCT02906605 - A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer Phase 2
Recruiting NCT05743621 - Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer Phase 1
Completed NCT02204072 - BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) Phase 1
Recruiting NCT05393791 - Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC Phase 2
Completed NCT03927391 - Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects Phase 4
Recruiting NCT06353386 - Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) Phase 1/Phase 2
Active, not recruiting NCT03431350 - A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT03822845 - Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer Phase 2/Phase 3
Completed NCT02162836 - A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer Phase 1
Completed NCT02899104 - Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
Active, not recruiting NCT04381832 - Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer Phase 1/Phase 2
Completed NCT03563014 - A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
Active, not recruiting NCT05968599 - A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Active, not recruiting NCT02803437 - Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
Recruiting NCT05944237 - HTL0039732 in Participants With Advanced Solid Tumours Phase 1/Phase 2
Withdrawn NCT03173859 - Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients Phase 2
Terminated NCT02057666 - Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer Phase 3
Active, not recruiting NCT04717154 - Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer Phase 2